Page 54 - GALENIKA MEDICAL JOURNAL

Abstract

Primary (essential) hypertension includes about 90% of all cases of hypertension, and the treatment is symptomatic. As the
response to the need for suppression of sympathetic activity in the regulation of hypertension, central antihypertensives
have been developed, through central and peripheral adrenergic and non-adrenergic mechanisms, to affect the reduction
of sympathetic nerve activity, inhibition of norepinephrine release, reduction of systemic vascular resistance, peripheral
vasodilatation, reduction of heart rate and lowering of blood pressure. Moxonidine has been proven to be effective and
safe, whether used as monotherapy or in combination in the treatment of hypertension in which sympathetic hyperactivity
predominates, especially in patients with metabolic syndrome, obese patients, patients with prehypertension and stress-
induced hypertension with catecholamine hyperactivity.

Keywords: treatment of hypertension, central antihypertensives, moxonidine

Literatura 15. Zeltner N, Wu HF, Saito-Diaz K, Sun X, Song M, Saini T, et al. A modular
platform to generate functional sympathetic neuron-innervated heart
assembloids. Res Sq [Preprint]. 2024: rs.3.rs-3894397.
1. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension 16. Wang Y, Nguyen DT, Anesi J, Alramahi A, Witting PK, Chai Z, et al.
Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 Jun Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in
18;73(23):3018-26. Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in
2. Pandrc M, Kostovski V. Metabolic neutral nephroprotective Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023;24(4):3857.
antihypertensive drugs: Beta blockers and calcium channel blockers. 17. Sanjuliani AF, Francischetti EA, Genelhu de Abreu V Ueleres Braga J.
Galenika Medical Journal 2023; 2(6): 34-38. Effects of Moxonidine on the Sympathetic Nervous System, Blood
3. Marieb E, Hoehn K. Human Anatomy and Physiology. 9th ed. San Pressure, Plasma Renin Activity, Plasma Aldosterone, Leptin, and
Francisco, CA: Pearson; 2011; p:692-751. Metabolic Profile in Obese Hypertensive Patients. Journal of Clinical and
Basic Cardiology 2004; 7 (1-4), 19-25.
4. Kotchen TA. Harrison's Principles of Internal Medicine. 18th ed. 2012;
p:2042-59. 18. Cincotta AH. Brain Dopamine-Clock Interactions Regulate
Cardiometabolic Physiology: Mechanisms of the Observed
5. Elliot WJ. Et al. Hurst’s The Heart. 11th ed. New York: McGraw-Hill Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy
Companies; 2004; 1531-73. in Type 2 Diabetes Subjects. Int J Mol Sci. 2023;24(17):13255.
6. Kishi T. Clarification of hypertension mechanisms provided by the 19. Mannozzi J, Massoud L, Stavres J, Al-Hassan MH, O'Leary DS. Altered
research of central circulatory regulation. Hypertens Res. 2023 Autonomic Function in Metabolic Syndrome: Interactive Effects of
;46(8):1908-16. Multiple Components. J Clin Med. 2024;13(3):895.
7. Ikeda S, Shinohara K, Enzan N, Matsushima S, Tohyama T, Funakoshi 20. Stefan N, Schulze MB. Metabolic health and cardiometabolic risk
K, et al. A higher resting heart rate is associated with cardiovascular clusters: implications for prediction, prevention, and treatment. Lancet
event risk in patients with type 2 diabetes mellitus without known Diabetes Endocrinol. 2023;11(6):426-40.
cardiovascular disease. Hypertens Res. 2023 May;46(5):1090-9.
21. Valensi P. Autonomic nervous system activity changes in patients
8. Lindgren M, Robertson J, Adiels M, Schaufelberger M, Åberg M, Torén with hypertension and overweight: role and therapeutic implications.
K, et al. Elevated resting heart rate in adolescent men and risk of heart Cardiovasc Diabetol. 2021;20(1):170.
failure and cardiomyopathy. ESC Heart Fail. 2020 Jun;7(3):1178-85.
22. Waters J, Ashford J, Jäger B, Verboom CN, Wonnacott S. Use of
9. Zicha J, Řezáčová L, Behuliak M, Vaněčková I. Blood pressure reduction moxonidine as initial therapy and in combination in the treatment of
induced by chronic intracerebroventricular or peroral clonidine essential hypertension - results of the TOPIC (Trial of Physiotens in
administration in rats with salt-dependent or angiotensin II-dependent Combination) Study. Journal of Clinical and Basic Cardiology 1999; 2 (2):
hypertension. Physiol Res. 2022 ;71(6):763-70. 219-24.
10. Karlafti EF, Hatzitolios AI, Karlaftis AF, Baltatzi MS, Koliakos GG, 23. Darabont RO, Gheorghe-Fronea OF, Bumbacea R, Vornicu R, Andrei
Savopoulos CG. Effects of moxonidine on sympathetic nervous system CL. An Actual Perspective on I1-Imidazoline Agonists in Blood Pressure
activity: An update on metabolism, cardio, and other target-organ Control. Results of a Multicentric Observational Prospective Study.
protection. J Pharm Bioallied Sci. 2013;5(4):253-6. Maedica (Bucur). 2023;18(4):547-54.
11. Palatini Chazova I, Schlaich MP. Improved Hypertension Control with 24. Lamptey RNL, Sun C, Layek B, Singh J. Neurogenic Hypertension,
the Imidazoline Agonist Moxonidine in a Multinational Metabolic the Blood-Brain Barrier, and the Potential Role of Targeted
Syndrome Population: Principal Results of the MERSY Study. Int J Nanotherapeutics. Int J Mol Sci. 2023;24(3):2213.
Hypertens. 2013; 2013:541689.
12. Mancia G, Di Rienzo M, Parati G, Grassi G. Sympathetic activity, blood
pressure variability and end organ damage in hypertension. J Hum Konflikt interesa: Nema
Hypertens. 1997;11 Suppl 1: S3-8.
Primljeno: 25. 07. 2024.
13. Hendry E, McCallister B, Elman DJ, Freeman R, Borsook D, Elman I.
Validity of mental and physical stress models. Neurosci Biobehav Rev. Prihvaćeno: 29. 08. 2024.
2024; 158:105566. Onlajn: 01. 09. 2024.
14. Casanova-Lizón A, Manresa-Rocamora A, Flatt AA, Sarabia JM, Moya-
Ramón M. Does Exercise Training Improve Cardiac-Parasympathetic
Nervous System Activity in Sedentary People? A Systematic Review with
Meta-Analysis. Int J Environ Res Public Health. 2022;19(21):13899.

52 DOI: 10.5937/Galmed2411044P